MSF calls for new price of anti TB drug delamanid to be lowered
Doctors Without Borders (MSF) acknowledges the lower price offered to the government of South Africa for newer anti tuberculosis (TB) drug, delamanid, but calls for it to be significantly lower and expanded to all countries in need. Mylan, which licenses the drug from the patent-holder Otsuka, will charge about R14 000 (US$940*) for a six-month…